Influenza

Safety, Tolerability, and Immunogenicity of Different Combinations of Trivalent Influenza Vaccine Varying Influenza Antigen Dose, Adjuvant Dose, and Route of Administration in Healthy Elderly Individuals Ages 65 Years and Older

NCT00848848 | PHASE 1 | INTERVENTIONAL

The study will evaluate the safety, tolerability and immunogenicity of different doses and types of Influenza Vaccine in healthy elderly subjects.

1 Sites

450 Participants

Recruiting

65 Years to 75 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

Center For Vaccinology

Ghent,Belgium,9000

Study Eligibility Criteria

Inclusion Criteria

* Subjects 65 years or older generally in good health as determined by medical history, physical assessment and clinical judgment of the investigator.

Exclusion Criteria

* Subjects who have received influenza vaccine within the past 6 month and who have received adjuvanted vaccine in the past two years.
* Subjects with hypersensitivity to vaccine components. Subjects who are on or were recently on immunosuppressive therapy.

Additional Studies

Additional studies can be found at ClinicalTrials.gov